Full
Outline
To evaluate the efficacy of sintilimab plus bevacizumab combined with hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) and explore their effects of this combined regimen on macrophage function and phenotype.
Patients with advanced HCC admitted to a hospital from September 2022 to May 2024 were prospectively selected and randomly divided into a control group and an observation group, with 50 cases in each group.The control group received HAIC alone, while the observation group received HAIC combined with sintilimab and bevacizumab. The differences in short-term clinical efficacy, functional indices, and adverse reactions between the two groups were compared.A 6-month follow-up was conducted on patients in both groups after the end of treatment to evaluate long-term efficacy.
After treatment, the observation group exhibited higher disease control rate (DCR), objective response rate (ORR), median progression-free survival (PFS), mean overall survival (OS), macrophage count, proportion of anti-tumor phenotype (M1 type) macrophages, and counts of CD3+, CD4+, and CD8+ T lymphocytes compared to the control group (all P < 0.05). The observation group also showed lower levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), proportion of immunosuppressive phenotype (M2 type) macrophages, and interleukin-6 (all P < 0.05). The incidence of adverse reactions was lower in the observation group, though the difference was not statistically significant (all P > 0.05).
The combination of sintilimab and bevacizumab with HAIC in the treatment of advanced hepatocellular carcinoma can effectively improve short-term and long-term clinical efficacy, improve liver function, regulate macrophage function and phenotype, and enhance the cellular immune function of patients.
108
28
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
